A four-page spread consisting of an interview with TAAT™ CEO Setti Coscarella was published in the December 17, 2020 edition of the CSE’s Public Entrepreneur magazine in which Mr. Coscarella details his journey from the world’s largest tobacco company to TAAT™, as well as his near-term and long-term plans for the Company. Additionally, on December 18, 2020 the Company was added to the CSE Composite Index® as well as a subset of the 25 largest companies in the index by market capitalization known as the CSE25™ index.
LAS VEGAS and VANCOUVER, DECEMBER 22, 2020 – TAAT™ LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “TAAT™”) is pleased to announce that an interview with its Chief Executive Officer Setti Coscarella was featured in the December 17, 2020 edition of Public Entrepreneur magazine, a digital periodical published by the Canadian Securities Exchange (“CSE”), which succeeded the CSE Quarterly, the CSE’s legacy publication, in the spring of 2018. The interview was led by Jon Hopkins, a 25-year veteran of financial journalism, based out of Greater London covering North American and U.K. markets. Additionally, as of Friday December 18, 2020, the Company’s equity has been added to both the CSE Composite Index® and CSE25™ index. After becoming a post-revenue company earlier this month, the Company’s management is pleased to receive this public recognition of its achievements to date in the North American capital markets.
In the Public Entrepreneur magazine interview, Setti Coscarella discusses macro-level changes that have taken place in the tobacco industry, and how such changes prompted his transition from a strategist role at Philip Morris International to a leadership role in a new company such as TAAT™. In addition to providing further detail on the TAAT™ product and its current launch in Ohio, Mr. Coscarella also describes the Company’s aspirations to expand internationally, the approximate size of the market being targeted by the Company, and what investors can expect from the management of TAAT™ going forward.
“While others sell difference, we sell similarity, and for a transition such as giving up tobacco, similarity is priceless.”
Quote from TAAT™ Chief Executive Officer Setti Coscarella in an interview published in the CSE’s Public Entrepreneur magazine last week
Beginning of Setti Coscarella’s interview in the December 17, 2020 edition of Public Entrepreneur, where Mr. Coscarella describes his transition from PMI to TAAT™ and his visions for commercializing TAAT™ in the USD $814 global tobacco industry. The online edition of this magazine issue can be accessed by clicking here. Mr. Coscarella’s interview begins on page 20.
Readers using news aggregation services may be unable to view the media above. Please access SEDAR or the Investor Relations section of the Company’s website for a version of this press release containing all published media.
The CSE Composite Index® provides approximately 75% coverage of all equities listed on the CSE, and consists primarily of firms in the Life Sciences sector. The CSE25™ index is a subset of the CSE Composite Index®, consisting of securities of the top 25 companies by market capitalization. Inclusive of TAAT™ and the 24 other companies comprising the index, the CSE25™ has a combined portfolio capitalization of approximately CAD $28.1 billion as of market pre-open on December 22, 2020.
“It was a pleasure to be interviewed for the CSE’s Public Entrepreneur magazine, as I believe it was an excellent opportunity to share my story and discuss how it aligns with the Company’s roadmap”, said Setti Coscarella, Chief Executive Officer of TAAT™. “Now that TAAT™ is on store shelves in our initial market and we have become a post-revenue company, I believe it is important for the capital markets to understand the big picture of where we plan to take TAAT™ as a novel alternative to tobacco cigarettes for legal-aged smokers. It was exactly six months ago to the day that TAAT™ started trading on the CSE on June 22, 2020, and it is a testament to everyone’s hard work that we have not only already been added to the CSE Composite Index®, but also that we are among the 25 largest firms in that index by market capitalization. We look forward to continuing this momentum to potentially bring 2020 to a strong finish and hopefully make 2021 a prosperous year as we work towards capturing market share in the USD $814 global tobacco industry.”
On behalf of the Board of Directors of the Company,
TAAT™ LIFESTYLE & WELLNESS LTD.
Setti Coscarella, CEO and Director
For further information, please contact:
TAAT™ Investor Relations
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT™ Lifestyle & Wellness Ltd.
The Company has developed TAAT™, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. TAAT™’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT™ is launching in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion1 global tobacco industry.
For more information, please visit https://taatglobal.com.
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the potential launch of Beyond Tobacco™, in addition to the following: Potential outcomes from the Company’s addition to the CSE Composite Index® and the CSE25™ index. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT™ Lifestyle & Wellness Ltd. can be found under the Company’s profile on http://sedar.com.